GlycoMimetics, Inc. (GLYC) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for joining the GlycoMimetics Investor and Analyst. On this note, this event is being recorded. Today's remarks will be followed by a question and answer session with the management team. Please dial in via telephone to participate. I would now like to turn the conference over to Christian Denning-Long, Company Counsel at GlycoMimetics. Please go ahead. Good morning. Today we will review top-line results from our Phase III study of our lead drug candidate, upralesolin. A press release was issued this morning and is available on the company's website at glycomimetics.com. This call is being recorded, and a dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website. On the call today from Glycomimedics are Harit Samarjan, Chief Executive Officer, and Dr. Edwin Rock, Chief Medical Officer. Brian Hahn, the company's Chief Financial Officer, will also be available for the question and answer session. Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidate, UproLessolan, and analysis of data from the company-sponsored Phase III clinical trial. the progress and timing of clinical trials being conducted by our collaborators, including expectations regarding data readout from those trials, planned or potential data presentation, regulatory and development plans and activities, and the company's cash burn and budget plan. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. Glycomatics undertakes no obligation to...